Cemiplimab( —— )

Catalog No. M36699 CAS No. 1801342-60-8

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Get Quotation Bulk Inquiry Add to Cart

Product Name

Cemiplimab
Note

Research use only, not for human use.
Brief Description

Cemiplimab (Anti-Human PD-1) is a human monoclonal antibody that inhibits the PD-1/PD-L1 pathway, serving as a checkpoint inhibitor.
Description

Cemiplimab (Anti-Human PD-1) is a high-affinity programmed death receptor-1 (PD-1) monoclonal IgG4 antibody that blocks PD-1/PD-L1-mediated T-cell suppression. Cemiplimab is commonly used in squamous cell skin cancer research.
In Vitro

——
In Vivo

Cemiplimab (i.p., 10 mg/kg, five injections within 2 weeks) can increased the proportion of effector T cells in tumors and dLNs to reduce tumor growth by combined immunotherapy with REGN3767 in MC38.Ova tumor mice model.Animal Model:Female human PD-1×LAG-3 knockin mice (8-10 weeks) with MC38.Ova cells Dosage:10 mg/kg Administration:Intraperitoneal injection; five injections within 2 weeks Result:Partially inhibited the growth of MC38.Ova tumors and prolonged the survival of mice by administering alone.Significantly increased the proportion of CD4+ TILs in IFNγ and TNFα by combined immunotherapy with REGN3767.
Synonyms

——
Pathway

Others
Target

Other Targets
Recptor

Others
Research Area

——
Indication

——

1. Michael R Migden, et al. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med. 2018 Jul 26;379(4):341-351.?

Calculator

molnova catalog